This Phase 2 study was designed to test, in Thai adults, safety and immunogenicity of RTS,S/AS01 administered in conjunction with anti-malarial drugs. If results are promising, it will form the basis for assessing the impact of RTS,S/AS01 vaccination in targeted malaria elimination programs in the Greater Mekong Subregion.
Tun KM, Imwong M, Lwin KM, Win AA, Hlaing MM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. The Lancet Infectious Diseases. 2015 Feb 19; 15(4): 415-21.
ClinicalTrials.gov Identifier: NCT02992119